Medtronic, Inc. (MDT) PT Raised to $94 at BMO Capital on 4Q Beat; 'Strength Across Franchises'
BMO Capital raised its price target on Medtronic, Inc. (NYSE: MDT) to $94.00 (from $87.00) while maintaining a Outperform rating, following the company's fourth quarter earnings report.
Analyst Joanne Wuensch notes the company delivered fourth quarter earnings per share and revenues above consensus expectations, as management has benefited from robust operating leverage resulting in strength across franchises.